Kidney Patients With Diabetes: Managing Their Medication

Author and Disclosure Information

Although accreditation for this CE/CME activity has expired, and the posttest is no longer available, you can still read the full article.

Expires February 28, 2015

Because the vast majority of patients with chronic kidney disease (CKD) are diabetic and thus take hypoglycemic medications, knowledge of renal dosing for these medications, their mechanisms of action, and their safety profiles, as well as consideration of A1C goals, is vital for the practicing clinician. Management of the diabetic CKD patient, identified by stage of kidney disease, is outlined, with dosing regimens as determined by the glomerular filtration rate. Special attention is given to insulin management.



CE/CME No: CR-1402

Earn credit by reading this article and successfully completing the posttest. Successful completion is defined as a cumulative score of at least 70% correct.

• Discuss the incidence and staging of chronic kidney disease (CKD).
• Enumerate the treatment goals for the CKD patient with diabetes.
• Describe the hypoglycemic medications that can be used at each stage of CKD.

Cheryl Gilmartin is a Clinical Pharmacist in Nephrology and a Clinical Assistant Professor in the College of Pharmacy at the University of Illinois at Chicago. Jane S. Davis, a member of the Clinician Reviews editorial board, is a nurse practitioner in the Division of Nephrology at the University of Alabama at Birmingham and is the communications chairperson for the National Kidney Foundation’s Council of Advanced Practitioners (NKF-CAP). Kim Zuber, past chair of the NKF-CAP, is a physician assistant with Metropolitan Nephrology in Alexandria, Virginia, and Clinton, Maryland.


This program has been reviewed and is approved for a maximum of 1.0 hour of American Academy of Physician Assistants (AAPA) Category I CME credit by the Physician Assistant Review Panel. [NPs: Both ANCC and the AANP Certification Program recognize AAPA as an approved provider of Category 1 credit.] Approval is valid for one year from the issue date of February 2014.

Article begins on next page >>


Next Article: